TUBB3 and triple-negative breast carcinoma: Even though alteration of β-tubulin subtypes may affect the anti-cancer effectiveness of paclitaxel, the discovery of new biomarkers other than TUBB3 to predict clinical outcomes in patients with HER2-positive and triple-negative breast cancers prior to receiving paclitaxel-based chemotherapy is likely valuable.